Repligen | RGEN - Net Income


Repligen reported $8.33M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Agilent USD 339M 34M Mar/2026
Align Technology USD 112.77M 22.99M Mar/2026
Bio Techne USD 51.05M 13.04M Mar/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Bruker USD 3.5M 22.5M Mar/2026
Charles River Laboratories USD -14.84M 261.71M Mar/2026
Danaher USD 1.03B 168M Mar/2026
Dentsply International USD -10M 136M Mar/2026
General Electric Aerospace USD 1.9B 637M Mar/2026
Henry Schein USD 107M 6M Mar/2026
Illumina USD 134M 200M Mar/2026
IQVIA Holdings USD 274M 240M Mar/2026
Mettler Toledo International USD 169.45M 116.31M Mar/2026
Myriad Genetics USD -7.9M 19.5M Dec/2025
OraSure Technologies USD -19.29M 5.57M Dec/2025
Pacific Biosciences Of California USD -40.37M 2.37M Dec/2025
Pfizer USD 2.69B 4.34B Mar/2026
Repligen USD 8.33M 4.95M Mar/2026
Revvity USD 40.72M 57.65M Mar/2026
Standard Biotools USD 19.28M 53.97M Dec/2025
Thermo Fisher Scientific USD 1.65B 313M Mar/2026
Waters USD -72M 297.21M Mar/2026
West Pharmaceutical Services USD 138.8M 6.7M Mar/2026